Take 3 drug stocks and call your broker in the morning. Wednesday GlaxoSmithKline (GSK) - the world's second biggest drug maker – closed nearly 3% higher after the company announced a $25 billion buyback, the fourth biggest buyback ever. Meanwhile, rival Eli Lilly (LLY) continued to run after crushing estimates Tuesday. And Merck (MRK) closed higher, too. Is big pharma poised to make a big move?
Guy Adami says GSK is a screaming buy although he anticipates a little more weakness from their Avandia drug.
Eric Bolling likes Merck (MRK) the best in this sector.
Pete Najarian adds that a new drug from GSK called "Alli" is the first over-the-counter weight-loss drug approved by the Food and Drug Administration and it's presenting a direct challenge for Nutrisystem (NTRI).
On a related note, in biotech he likes Amylin (AMLN) and Biogen (BIIB).
Got something to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to email@example.com.
Trader disclosure: On July 25th 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (ATVI), (JWN) Bolling Owns (BP), (XOM).